Study of Iparomlimab and Tuvonralimab for resectable lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests two immunotherapy drugs (iparomlimab and tuvonralimab) before and after surgery for people with a certain type of lung cancer that can be removed. It aims to see if this treatment helps improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older.
- You have non-small cell lung cancer (NSCLC) that has not been treated yet, stage II to IIIB (with lymph node involvement only in N2).
- Your tumor is considered removable by a team of doctors, including a lung cancer surgeon.
- You can provide a sample of your tumor tissue for testing.
- You have not had certain genetic mutations (EGFR or ALK) and have not received immunotherapy before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two immunotherapy drugs (iparomlimab and tuvonralimab) with stereotactic body radiation therapy (SBRT) for people with early-stage non-small cell lung cancer. The goal is to see if this treatment can help shrink or control the cancer before surgery.
This trial tests whether giving a drug called Toripalimab after surgery can help prevent early-stage non-squamous non-small cell lung cancer from coming back. It is for people whose tumors have high-risk features and PD-L1 levels of at least 1%.
This trial tests if two immunotherapy drugs (iparomlimab and tuvonralimab) combined with chemotherapy can shrink stage III lung cancer that cannot be surgically removed, making it possible to operate. It is for people who have not had prior treatment for their lung cancer and are healthy enough for surgery.
This trial tests two immunotherapy drugs (iparomlimab and tuvonralimab) combined with chemotherapy given before surgery to remove stage III lung cancer. The goal is to shrink the tumor and improve survival chances by boosting your immune system to fight the cancer.
This trial tests combining immunotherapy with chemotherapy for people with stage III non-small cell lung cancer that cannot be removed by surgery. It aims to see if this combination can shrink the tumor and improve outcomes.
This trial tests combining two immunotherapy drugs (iparomlimab and tuvonralimab) with 2 or 4 cycles of chemotherapy before surgery for patients with stage II to IIIB non-small cell lung cancer that can be removed. It aims to see if this approach helps shrink tumors and improve outcomes.
Hear when a new Non-small Cell Lung Cancer (NSCLC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.